Osteosarcoma Market

DelveInsight’s ‘Osteosarcoma-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


The Osteosarcoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Osteosarcoma market size from 2017 to 2030. The Report also covers current Osteosarcoma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Osteosarcoma Disease Understanding and Treatment Algorithm

Osteosarcoma Overview

Osteosarcoma (osteogenic sarcoma) is the most common type of bone cancer that usually develops in the osteoblast cells of the bone.


It mostly occurs in the long bones around the knee. Other sites include the upper leg, or thighbone, the lower leg, upper arm bone, or any bone in the body, including those in the pelvis, shoulder, and skull. It may spread to nearby tissues, such as tendons or muscles, and may also metastasize through the bloodstream to other organs or bones in the body.


It can be classified as primary or secondary based on the location and spread of cancer. When cancer starts in bone tissue, it is called primary bone cancer. Whereas, when cancer cells travel to the bone from elsewhere, it is called secondary or metastatic bone cancer.


Furthermore, based on the histological features, it can be categorized into high-grade, intermediate-grade, and low-grade Osteosarcoma; each category has different subtypes.


Pain is the most common symptom of Osteosarcoma; this pain may come and go at first, but, gradually, it becomes constant. Some patients may have swelling or a mass in the area of the tumor. If the tumor is located in the leg, the patient may also develop a limp.


Osteosarcoma weakens the bones, and patients may develop pathologic bone fractures in the area of the tumor.

Osteosarcoma Diagnosis

The signs or symptoms first suspect the diagnosis of Osteosarcoma. The diagnosis usually started by examining the medical history and physical examination. Imaging techniques, blood tests, and biopsy are used to confirm the diagnosis of Osteosarcoma and classification into stages.


Continued in the report…..

Osteosarcoma Treatment

Osteosarcoma is treated with a combination of therapies that can include surgery, chemotherapy, and radiation therapy. Most patients with high-grade tumors receive about 3 months of chemotherapy, known as neoadjuvant therapy, before surgery.


Most osteosarcomas are high-grade and require multimodal treatment, mainly chemotherapy, and surgery. Low-grade osteosarcoma (including parosteal and low-grade central) does not require chemotherapy, but if the histological examination of a resected tumor shows high-grade areas, chemotherapy is recommended.


The most common combinations of chemotherapy include high-dose methotrexate, doxorubicin, and cisplatin (sometimes with ifosfamide); doxorubicin and cisplatin; ifosfamide and etoposide; and ifosfamide, cisplatin (or carboplatin), and epirubicin.

Osteosarcoma Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

  • As per DelveInsight estimates, the Incident cases of Osteosarcoma in the 7MM were 2,181 cases in 2017 during the study period (2017–2030).
  • The incident cases of Osteosarcoma in the United States was 1,141 patients in 2017.
  • Our Reports estimate that males have higher cases in comparison to females. In 2017, males and females accounted for 602 and 539 cases of Osteosarcoma.
  • Based on the stages of cancer, Osteosarcoma is categorized into localized, regional, and distant stages. Localized and regional are further defined as non-metastatic, whereas, the ‘distant’ stage is defined as metastasis. The localized and regional stage incident cases accounted for 377 and 548 cases in 2017. In the same year, distant staged Osteosarcoma cases contributed to 217 cases in the US.
  • Osteosarcoma is classified into various subtypes based on the histological findings. The most common subtypes based on the various published studies are conventional, telangiectatic, parosteal, periosteal, and other Osteosarcoma. In the US, Conventional osteosarcoma accounted for nearly 80% of total osteosarcoma cases. Remaining ~20% cases include telangiectatic, parosteal, periosteal, and other Osteosarcoma.
  • In the EU5, the highest Incident cases were reported to be in Germany followed by France and the United Kingdom whereas the lowest Incident cases were reported in Spain from 2017 through 2030.
  • Japan was reported to have 198 Incident cases in 2017.

Osteosarcoma Epidemiology

The epidemiology segment also provides the Osteosarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Osteosarcoma Drug Chapters

The drug chapter segment of the Osteosarcoma report encloses the detailed analysis of Osteosarcoma marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Osteosarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Osteosarcoma Marketed Drugs

Mepact (Mifamurtide): Takeda

Mepact is an intravenous formulation containing mifamurtide as an active ingredient. It is approved in children, adolescents, and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection and is used in combination with postoperative multiagent chemotherapy. Mepact is available as a vial containing powder for reconstitution and one single-use filter. The active substance in Mepact, mifamurtide, is an immunomodulator. It works by activating macrophages and monocytes. The precise way that mifamurtide works in osteosarcoma is not fully understood, but it is thought to cause the white blood cells to release chemicals that kill the cancerous cells. Mepact is not approved in the US; however, some osteosarcoma patients have been able to obtain Mepact in the United States through the FDA’s compassionate use and personal importation programs. The FDA also designated patient affairs staff that may help navigate the access process.

Products detail in the report…

Khapzory (levoleucovorin): Acrotech Biopharma

Khapzory (levoleucovorin) injection, folate analog, is approved for rescue after high-dose methotrexate therapy in patients with osteosarcoma. Rescue recommendations are based on a methotrexate dose of 12 grams/m2 administered by intravenous infusion over 4 h. The rescue is initiated at a dose of 7.5 mg (approximately 5 mg/m2) every 6 h, 24 h after the beginning of the methotrexate infusion and is continued until the methotrexate level is below 0.05 µM. Khapzory is available as an intravenous administration only. It is also approved for diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination and for treatment of patients with metastatic colorectal cancer in combination with fluorouracil.


Products detail in the report…

Osteosarcoma Emerging Drugs

Lenvatinib: Eisai Limited

Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2, and VEGFR3 kinases. Currently, the company is investigating this molecule in Phase II stage of development for Osteosarcoma.

Products detail in the report…

Regorafenib: Bayer

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). This drug shows anti-angiogenic activity due to its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. Currently. The company is evaluating this molecule in Phase II stage of development for the treatment of patients with Osteosarcoma.

Products detail in the report…

Cabozantinib S-malate: Exelixis

Cabozantinib sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second-line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Currently, the company is investigating this molecule in Phase II stage of development for the treatment of patients with advanced Ewing sarcoma or osteosarcoma.


Products detail in the report…


List to be continued in the report…

Osteosarcoma Market Outlook

The United States contributes to the major share of the Osteosarcoma market as compared to other countries, such as EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan.


In general, the commonly available modalities for the treatment of osteosarcoma include chemotherapy, surgery and radiation therapy.


Although some novel insights have been offered for clinical and scientific relevance, minor progress has been made in Osteosarcoma treatment following a significant survival improvement in the late 1980s with the addition of chemotherapy to surgery. The most widely used chemotherapeutic drugs include cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin calcium rescue (HDMTX), or a combination of these. The use of these agents results in an approximately 60–70% increase in the overall survival.


However, successful treatment is obtained in about ~70% of patients with localized disease and ~20–30% with the metastatic disease which shows that disease in the later stages has a poor prognosis.


The mainstream chemotherapeutic agents for treatment include methotrexate, doxorubicin, cisplatin, and ifosfamide approved by the NCCN Guidelines. Since the introduction of chemotherapy, single-agent treatment of osteosarcoma is considered inadequate, the majority of osteosarcoma treatment is based on a combination of two or more of only four drugs: doxorubicin, cisplatin, methotrexate, and ifosfamide. Therefore, treatment options available for first-line osteosarcoma patients consist of combinations including doxorubicin + cisplatin (DC), methotrexate + doxorubicin + cisplatin (MDC), and methotrexate + doxorubicin + cisplatin + ifosfamide (MDCI).


The function of second-line chemotherapy for recurrent Osteosarcoma is much less well defined and there is no accepted standard regimen. The National Comprehensive Cancer Network (NCCN) guidelines recommend that second-line (relapsed/refractory or metastatic) preferred therapies include ifosfamide (high dose) and etoposide, regorafenib, sorafenib, sorafenib Radium 223 chloride, and everolimus. Other preferred regimens include cyclophosphamide and topotecan, docetaxel and gemcitabine, gemcitabine alone.


The other regimens which are useful under certain circumstances as per NCCN guidelines include cyclophosphamide and etoposide, ifosfamide with carboplatin and etoposide, high dose methotrexate, high dose methotrexate with etoposide and ifosfamide, Sm-EDTMP for relapsed refractory disease beyond the second line.


Apart from these treatment regimens, there are few FDA approved products for osteosarcoma including Fusilev and Khapzory, both folate analogs used for the rescue after high-dose methotrexate therapy in patients with osteosarcoma. Fusilev was approved by FDA in 2008 and recently its patent got expired after that it was discontinued from the market. The company then introduced a drug Khapzory with the same generic (Levoleucovorin). The drug was later approved by the FDA in 2018 for the same indication.


Furthermore, In March 2009, the European Commission granted a marketing authorization valid throughout the European Union for Mepact to IDM Pharm.


This product is not approved in the United States. Nevertheless, some osteosarcoma patients have been able to obtain Mepact in the United States through the FDA’s compassionate use and personal importation programs. 


According to DelveInsight, Osteosarcoma 7MM is expected to change in the study period 2017–2030.

Key Findings

  • The therapeutic market of Osteosarcoma in the 7MM was USD 72.50 million in 2017.
  • The therapeutic market of Osteosarcoma in the United States was USD 25.84 million in the year 2017.
  • The therapeutic market of Osteosarcoma is classified into two stages i.e. Non-metastatic & Metastatic. In the US, the total market of Osteosarcoma was USD 25.84 million in 2017. Out of which, the non-metastatic market was approximately USD 3.86 million and the metastatic market was USD 21.97 million in the United States.
  • The metastatic market is further classified into three lines of therapies i.e. First-line, Second-line, and Third-line+. Out of the total metastatic market of USD 21.97 million in the US in 2017, USD 0.73 million accounted for First-line, USD 7.63 million accounted for Second-line and remaining USD 13.61 million accounted for Third-line+ of therapies.
  • Among the EU-5, Germany (USD 11.82 million) has the highest market size followed by France (USD 9.92 million) and the United Kingdom (USD 9.03 million).
  • There are five emerging therapies are expected to launch during the forecast period (2020-2030). These include Lenvatinib (Eisai Limited), Regorafenib (Bayer), Cabozantinib S-malate (Exelixis), Pazopanib Hydrochloride and Topotecan Hydrochloride (GSK), Bempegaldesleukin (NKTR-214) Plus Nivolumab (Nektar therapeutics).
  • Among all the emerging therapies, Cabozantinib S-malate (Exelixis), is expected to launch in the year 2023 and will generate a revenue of USD 4.45 million in its launch year in the 7MM.
  • The Therapeutic market of Osteosarcoma in Japan was estimated to be USD 2.16 million in the year 2017.

The United States Market Outlook

This section provides the total Osteosarcoma market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Osteosarcoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Osteosarcoma market size and market size by therapies in Japan are provided.

Osteosarcoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Osteosarcoma market or expected to get launched in the market during the study period 2017–2030. The analysis covers Osteosarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.  


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Osteosarcoma Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Osteosarcoma emerging therapies.

Reimbursement Scenario in Osteosarcoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities.


When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Osteosarcoma market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of Osteosarcoma, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Osteosarcoma epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Osteosarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Osteosarcoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Osteosarcoma market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Osteosarcoma market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Osteosarcoma. Launch of emerging therapies will significantly impact the Osteosarcoma market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Osteosarcoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Osteosarcoma Pipeline Analysis
  • Osteosarcoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Osteosarcoma Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Osteosarcoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Osteosarcoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Osteosarcoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Osteosarcoma total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Osteosarcoma market size during the forecast period (2020–2030)?
  • At what CAGR, the Osteosarcoma market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Osteosarcoma market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Osteosarcoma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Osteosarcoma?
  • What is the historical Osteosarcoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Osteosarcoma at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Osteosarcoma?
  • Out of the above-mentioned countries, which country would have the highest incident population of Osteosarcoma during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Osteosarcoma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Osteosarcoma in the US and Europe?
  • What are the Osteosarcoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Osteosarcoma?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Osteosarcoma?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteosarcoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Osteosarcoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Osteosarcoma?
  • What are the 7MM historical and forecasted market of Osteosarcoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Osteosarcoma.
  • To understand the future market competition in the Osteosarcoma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Osteosarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Osteosarcoma market.
  • To understand the future market competition in the Osteosarcoma market.

1. Key Insights

2. Executive Summary of Osteosarcoma

3. Osteosarcoma Market Overview at a Glance

3.1. Market Share (%) distribution by Country of Osteosarcoma in 2017

3.2. Market Share (%) distribution by Country of Osteosarcoma in 2030

4. Disease Background and Overview: Osteosarcoma (OS)

4.1. Introduction

4.2. Classification of Osteosarcoma

4.3. Symptoms

4.4. Causes and risk factors

4.5. Pathogenesis of Osteosarcoma

4.6. Biomarkers

4.7. Diagnosis

4.7.1. Diagnostic Algorithm

4.7.2. Staging of Osteosarcoma

4.7.3. Diagnostic Guidelines

5. Case Reports

5.1. Locally advanced osteosarcoma of the ethmoid sinus: A report of successful management

5.2. Very late relapse of high-grade osteosarcoma: A case report and review of the literature

5.3. Case report of maxillary osteosarcoma with up-to date review

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology

6.3. Total Incident Cases of Osteosarcoma in the 7MM

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Incident Cases of Osteosarcoma in the United States

7.3. Gender-specific Incident Cases of Osteosarcoma in the United States

7.4. Age-specific Incident Cases of Osteosarcoma in the United States

7.5. Stage-specific Incident Cases of Osteosarcoma in the United States

7.6. Sub-types specific Incident Cases of Osteosarcoma in the United States

7.7. Site-specific Incident Cases of Osteosarcoma in the United States

8. EU5 Epidemiology

8.1. Germany Epidemiology

8.1.1. Assumptions and Rationale

8.1.2. Total Incident Cases of Osteosarcoma in Germany

8.1.3. Gender-specific Incident Cases of Osteosarcoma in Germany

8.1.4. Age-specific Incident Cases of Osteosarcoma in Germany

8.1.5. Stage-specific Incident Cases of Osteosarcoma in Germany

8.1.6. Sub-types specific Incident Cases of Osteosarcoma in Germany

8.1.7. Site-specific Incident Cases of Osteosarcoma in Germany

8.2. France Epidemiology

8.2.1. Assumptions and Rationale

8.2.2. Total Incident Cases of Osteosarcoma in France

8.2.3. Gender-specific Incident Cases of Osteosarcoma in France

8.2.4. Age-specific Incident Cases of Osteosarcoma in France

8.2.5. Stage-specific Incident Cases of Osteosarcoma in France

8.2.6. Sub-types specific Incident Cases of Osteosarcoma in France

8.2.7. Site-specific Incident Cases of Osteosarcoma in France

8.3. Italy Epidemiology

8.3.1. Assumptions and Rationale

8.3.2. Total Incident Cases of Osteosarcoma in Italy

8.3.3. Gender-specific Incident Cases of Osteosarcoma in Italy

8.3.4. Age-specific Incident Cases of Osteosarcoma in Italy

8.3.5. Stage-specific Incident Cases of Osteosarcoma in Italy

8.3.6. Sub-types specific Incident Cases of Osteosarcoma in Italy

8.3.7. Site-specific Incident Cases of Osteosarcoma in Italy

8.4. Spain Epidemiology

8.4.1. Assumptions and Rationale

8.4.2. Total Incident Cases of Osteosarcoma in Spain

8.4.3. Gender-specific Incident Cases of Osteosarcoma in Spain

8.4.4. Age-specific Incident Cases of Osteosarcoma in Spain

8.4.5. Stage-specific Incident Cases of Osteosarcoma in Spain

8.4.6. Sub-types specific Incident Cases of Osteosarcoma in Spain

8.4.7. Site-specific Incident Cases of Osteosarcoma in Spain

8.5. United Kingdom Epidemiology

8.5.1. Assumptions and Rationale

8.5.2. Total Incident Cases of Osteosarcoma in the United Kingdom

8.5.3. Gender-specific Incident Cases of Osteosarcoma in the United Kingdom

8.5.4. Age-specific Incident Cases of Osteosarcoma in the United Kingdom

8.5.5. Stage-specific Incident Cases of Osteosarcoma in the United Kingdom

8.5.6. Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom

8.5.7. Site-specific Incident Cases of Osteosarcoma in the United Kingdom

9. Japan Epidemiology

9.1. Assumptions and Rationale

9.2. Total Incident Cases of Osteosarcoma in Japan

9.3. Gender-specific Incident Cases of Osteosarcoma in Japan

9.4. Age-specific Incident Cases of Osteosarcoma in Japan

9.5. Stage-specific Incident Cases of Osteosarcoma in Japan

9.6. Sub-types specific Incident Cases of Osteosarcoma in Japan

9.7. Site-specific Incident Cases of Osteosarcoma in Japan

10. Treatment of Osteosarcoma

10.1. Treatment Algorithm

10.2. Treatment Guidelines

10.2.1. Nation Comprehensive Cancer Network (NCCN) guidelines for osteosarcoma

10.2.2. ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment, and follow-up

10.2.3. UK guidelines for the management of bone sarcomas

11. Unmet Needs

12. Marketed Drugs

12.1. Mepact (Mifamurtide): Takeda

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Advantages and Disadvantages

12.1.4. Clinical Development

12.1.5. Clinical Trial Information

12.1.6. Safety and Efficacy

12.1.7. Product Profile

12.2. Khapzory (levoleucovorin): Acrotech Biopharma

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Advantages and Disadvantages

12.2.4. Clinical Development

12.2.5. Safety and Efficacy

12.2.6. Product Profile

13. Emerging Drugs

13.1. Key cross Competition

13.2. Regorafenib: Bayer

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.3.1.1. Clinical Trials Information

13.2.4. Safety and Efficacy

13.2.5. Product Profile

13.3. Cabozantinib S-malate: Exelixis

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.3.1. Clinical Trials Information

13.3.4. Safety and Efficacy

13.3.5. Product Profile

13.4. Bempegaldesleukin (NKTR-214): Nektar Therapeutics

13.4.1. Product Description

13.4.2. Other Developmental Activities

13.4.3. Clinical Development

13.4.3.1. Clinical Trials Information

13.4.4. Safety and Efficacy

13.4.5. Product Profile

13.5. Lenvatinib in Combination with Ifosfamide and Etoposide: Eisai

13.5.1. Product Description

13.5.2. Other Developmental Activities

13.5.3. Clinical Development

13.5.3.1. Clinical Trials Information

13.5.4. Safety and Efficacy

13.5.5. Product Profile

13.6. Danyelza (Naxitamab/Hu3F8): Y-mAbs Therapeutics

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.6.3.1. Clinical Trials Information

13.6.4. Safety and Efficacy

13.6.5. Product Profile

13.7. Pazopanib Hydrochloride (GW786034B/Votrient) and Topotecan Hydrochloride (Hycamtin): GlaxoSmithKline/Novartis

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.3.1. Clinical Trials Information

13.7.4. Safety and Efficacy

13.7.5. Product Profile

13.8. Nab-rapamycin (ABI-009) with Nivolumab: Aadi Bioscience

13.8.1. Product Description

13.8.2. Other Developmental Activities

13.8.3. Clinical Development

13.8.3.1. Clinical Trials Information

13.8.4. Safety and Efficacy

13.8.5. Product Profile

13.9. Pepinemab (VX15/2503): Vaccinex, Inc.

13.9.1. Product Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.9.3.1. Clinical Trials Information

13.9.4. Safety and Efficacy

13.9.5. Product Profile

13.10. Nivolumab With or Without Ipilimumab: National Cancer Institute/Assaf-Harofeh Medical Center

13.10.1. Product Description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.3.1. Clinical Trials Information

13.10.4. Safety and Efficacy

13.10.5. Product Profile

13.11. Inhaled Lipid-complexed Cisplatin (ILC): Eleison Pharmaceuticals

13.11.1. Product Description

13.11.2. Other Developmental Activities

13.11.3. Clinical Development

13.11.3.1. Clinical Trials Information

13.11.4. Product Profile

13.12. Aliqopa (Copanlisib, BAY80-6946): Bayer

13.12.1. Product Description

13.12.2. Other Developmental Activities

13.12.3. Clinical Development

13.12.3.1. Clinical Trials Information

13.12.4. Product Profile

13.13. AU101: Aurora biopharma

13.13.1. Product Description

13.13.2. Other Developmental Activities

13.13.3. Clinical Development

13.13.3.1. Clinical Trials Information

13.13.4. Safety and Efficacy

13.13.5. Product Profile

13.14. CAB-AXL-ADC (BA3011): BioAtla

13.14.1. Product Description

13.14.2. Other Developmental Activities

13.14.3. Clinical Development

13.14.3.1. Clinical Trials Information

13.14.4. Product Profile

13.15. LN-145 (Autologous tumor-infiltrating lymphocytes): Iovance Biotherapeutics

13.15.1. Product Description

13.15.2. Other Developmental Activities

13.15.3. Clinical Development

13.15.3.1. Clinical Trials Information

13.15.4. Product Profile

13.16. Arfolitixorin (Modufolin): Isofol Medical AB

13.16.1. Product Description

13.16.2. Other Developmental Activities

13.16.3. Clinical Development

13.16.3.1. Clinical Trials Information

13.16.4. Product Profile

13.17. Opdivo (nivolumab): Bristol-Myers Squibb

13.17.1. Product Description

13.17.2. Other Developmental Activities

13.17.3. Clinical Development

13.17.3.1. Clinical Trials Information

13.17.4. Product Profile

13.18. CB-103: Cellestia Biotech

13.18.1. Product Description

13.18.2. Other Developmental Activities

13.18.3. Clinical Development

13.18.3.1. Clinical Trials Information

13.18.4. Product Profile

14. Osteosarcoma: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Methodology

14.3. Attribute Analysis

14.4. Market Size of Osteosarcoma in the 7MM

14.5. Market Size of Osteosarcoma in the 7MM by Therapies

15. Key Market Forecast Assumptions

16. 7MM Market Outlook

16.1. The United States Market Size

16.1.1. Total Market size of Osteosarcoma

16.1.2. Market Size by Therapies

16.1.3. Market Size of Osteosarcoma by Line of Therapies

16.1.3.1. Market Size of Osteosarcoma (Non-Metastatic)

16.1.3.2. Market Size of Osteosarcoma (Metastatic)

17. EU5

17.1. Germany Market Size

17.1.1. Total Market Size of Osteosarcoma

17.1.2. Market Size by Therapies

17.1.3. Market Size of Osteosarcoma by Line of Therapies

17.1.3.1. Market Size of Osteosarcoma (Non-Metastatic)

17.1.3.2. Market Size of Osteosarcoma (Metastatic)

17.2. France Market Size

17.2.1. Total Market Size of Osteosarcoma

17.2.2. Market Size by Therapies

17.2.3. Market Size of Osteosarcoma by Line of Therapies

17.2.3.1. Market Size of Osteosarcoma (Non-Metastatic)

17.2.3.2. Market Size of Osteosarcoma (Metastatic)

17.3. Italy Market Size

17.3.1. Total Market size of Osteosarcoma

17.3.2. Market Size by Therapies

17.3.3. Market Size of Osteosarcoma by Line of Therapies

17.3.3.1. Market Size of Osteosarcoma (Non-Metastatic)

17.3.3.2. Market Size of Osteosarcoma (Metastatic)

17.4. Spain Market Size

17.4.1. Total Market size of Osteosarcoma

17.4.2. Market Size by Therapies

17.4.3. Market Size of Osteosarcoma by Line of Therapies

17.4.3.1. Market Size of Osteosarcoma (Non-Metastatic)

17.4.3.2. Market Size of Osteosarcoma (Metastatic)

17.5. The United Kingdom Market Size

17.5.1. Total Market size of Osteosarcoma

17.5.2. Market Size by Therapies

17.5.3. Market Size of Osteosarcoma by Line of Therapies

17.5.3.1. Market Size of Osteosarcoma (Non-Metastatic)

17.5.3.2. Market Size of Osteosarcoma (Metastatic)

18. Japan

18.1. Japan Market Size

18.1.1. Total Market size of Osteosarcoma

18.1.2. Market Size by Therapies

18.1.3. Market Size of Osteosarcoma by Line of Therapies

18.1.3.1. Market Size of Osteosarcoma (Non-Metastatic)

18.1.3.2. Market Size of Osteosarcoma (Metastatic)

19. Market Drivers

20. Market Barriers

21. SWOT Analysis

22. Reimbursement and Market Access

23. KOL Views

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Tables

Table 1 Summary of Osteosarcoma, Market, Epidemiology and Key Events (2017–2030)

Table 2 Enneking MSTS staging system

Table 3 AJCC staging system for bone sarcoma

Table 4 Total Incident Cases of Osteosarcoma in the 7MM (2017–2030)

Table 5 Total Incident Cases of Osteosarcoma in the US (2017–2030)

Table 6 Gender-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Table 7 Age-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Table 8 Stage-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Table 9 Sub-types specific Incident Cases of Osteosarcoma in the US (2017–2030)

Table 10 Site-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Table 11 Total Incident Cases of Osteosarcoma in Germany (2017–2030)

Table 12 Gender-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Table 13 Age-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Table 14 Stage-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Table 15 Sub-types specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Table 16 Site-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Table 17 Total Incident Cases of Osteosarcoma in France (2017–2030)

Table 18 Gender-specific Incident Cases of Osteosarcoma in France (2017–2030)

Table 19 Age-specific Incident Cases of Osteosarcoma in France (2017–2030)

Table 20 Stage-specific Incident Cases of Osteosarcoma in France (2017–2030)

Table 21 Sub-types specific Incident Cases of Osteosarcoma in France (2017–2030)

Table 22 Site-specific Incident Cases of Osteosarcoma in France (2017–2030)

Table 23 Total Incident Cases of Osteosarcoma in Italy (2017–2030)

Table 24 Gender-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Table 25 Age-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Table 26 Stage-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Table 27 Sub-types specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Table 28 Site-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Table 29 Total Incident Cases of Osteosarcoma in Spain (2017–2030)

Table 30 Gender-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Table 31 Age-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Table 32 Stage-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Table 33 Sub-types specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Table 34 Site-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Table 35 Total Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Table 36 Gender-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Table 37 Age-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Table 38 Stage-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Table 39 Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Table 40 Site-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Table 41 Total Incident Cases of Osteosarcoma in Japan (2017–2030)

Table 42 Gender-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Table 43 Age-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Table 44 Stage-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Table 45 Sub-types specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Table 46 Site-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Table 47 Osteosarcoma systemic therapy agents of the NCCN guidelines

Table 48 MAP chemotherapy schedule

Table 49 Systemic therapy agents for osteosarcoma

Table 50 Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System)

Table 51 Sarcoma advisory group guidelines for osteosarcoma

Table 52 Mifamurtide, Clinical Trial Description, 2020

Table 53 Comparison of emerging drugs under development

Table 54 Regorafenib, Clinical Trial Description, 2020

Table 55 Cabozantinib S-malate, Clinical Trial Description, 2020

Table 56 Bempegaldesleukin, Clinical Trial Description, 2020

Table 57 Lenvatinib in Combination With Ifosfamide and Etoposide, Clinical Trial Description, 2020

Table 58 Danyelza (Naxitamab/Hu3F8), Clinical Trial Description, 2020

Table 59 Pazopanib Hydrochloride in combination with Topotecan Hydrochloride, Clinical Trial Description, 2020

Table 60 Nab-rapamycin (ABI-009) with Nivolumab, Clinical Trial Description, 2020

Table 61 Pepinemab, Clinical Trial Description, 2020

Table 62 Nivolumab With or Without Ipilimumab, Clinical Trial Description, 2020

Table 63 Inhaled Lipid-complexed Cisplatin, Clinical Trial Description, 2020

Table 64 Aliqopa (copanlisib, BAY80-6946), Clinical Trial Description, 2020

Table 65 AU101, Clinical Trial Description, 2020

Table 66 CAB-AXL-ADC (BA3011), Clinical Trial Description, 2020

Table 67 LN-145, Clinical Trial Description, 2020

Table 68 Arfolitixorin (Modufolin), Clinical Trial Description, 2020

Table 69 Nivolumab, Clinical Trial Description, 2020

Table 70 CB-103, Clinical Trial Description, 2020

Table 71 Seven Major Market Size of Osteosarcoma in USD Million (2017–2030)

Table 72 7 Major Market Size of Osteosarcoma by therapies in USD Million (2017–2030)

Table 73 Key Market Forecast Assumptions for Lenvatinib

Table 74 Key Market Forecast Assumptions for Regorafenib

Table 75 Key Market Forecast Assumptions for Cabozantinib S-malate

Table 76 Key Market Forecast Assumptions for Pazopanib Hydrochloride

Table 77 Key Market Forecast Assumptions for Bempegaldesleukin

Table 78 Market Size of Osteosarcoma in the United States, USD Million (2017–2030)

Table 79 United States Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 80 United States Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 81 United States Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Table 82 Market Size of Osteosarcoma in Germany, USD Million (2017–2030)

Table 83 Germany Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 84 Germany Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 85 Germany Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Table 86 Market Size of Osteosarcoma in France, USD Million (2017–2030)

Table 87 France Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 88 France Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 89 France Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Table 90 Market Size of Osteosarcoma in Italy, USD Million (2017–2030)

Table 91 Italy Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 92 Italy Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 93 Italy Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Table 94 Market Size of Osteosarcoma in Spain, USD Million (2017–2030)

Table 95 Spain Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 96 Spain Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 97 Spain Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Table 98 Market Size of Osteosarcoma in the United Kingdom, USD Million (2017–2030)

Table 99 United Kingdom Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 100 United Kingdom Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 101 United Kingdom Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Table 102 Market Size of Osteosarcoma in Japan, USD Million (2017–2030)

Table 103 Japan Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Table 104 Japan Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Table 105 Japan Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

List of Figures

Figure 1 Biologic growth pattern of osteosarcomas

Figure 2 Symptoms of osteosarcoma

Figure 3 Risk factors of osteosarcoma

Figure 4 Epigenetic events which may contribute to the initiation and progression of OS

Figure 5 Participation of microRNAs (miRs) in OS development

Figure 6 Role of lncRNAs and circRNAs in osteosarcoma

Figure 7 General diagnostic strategy for bone sarcomas

Figure 8 Total Incident Cases of Osteosarcoma in the 7MM (2017–2030)

Figure 9 Total Incident cases of Osteosarcoma in the US (2017–2030)

Figure 10 Gender-specific Incident cases of Osteosarcoma in the US (2017–2030)

Figure 11 Age-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Figure 12 Stage-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Figure 13 Sub-types specific Incident Cases of Osteosarcoma in the US (2017–2030)

Figure 14 Site-specific Incident Cases of Osteosarcoma in the US (2017–2030)

Figure 15 Total Incident cases of Osteosarcoma in Germany (2017–2030)

Figure 16 Gender-specific Incident cases of Osteosarcoma in Germany (2017–2030)

Figure 17 Age-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Figure 18 Stage-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Figure 19 Sub-types specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Figure 20 Site-specific Incident Cases of Osteosarcoma in Germany (2017–2030)

Figure 21 Total Incident cases of Osteosarcoma in France (2017–2030)

Figure 22 Gender-specific Incident cases of Osteosarcoma in France (2017–2030)

Figure 23 Age-specific Incident Cases of Osteosarcoma in France (2017–2030)

Figure 24 Stage-specific Incident Cases of Osteosarcoma in France (2017–2030)

Figure 25 Sub-types specific Incident Cases of Osteosarcoma in France (2017–2030)

Figure 26 Site-specific Incident Cases of Osteosarcoma in France (2017–2030)

Figure 27 Total Incident cases of Osteosarcoma in Italy (2017–2030)

Figure 28 Gender-specific Incident cases of Osteosarcoma in Italy (2017–2030)

Figure 29 Age-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Figure 30 Stage-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Figure 31 Sub-types specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Figure 32 Site-specific Incident Cases of Osteosarcoma in Italy (2017–2030)

Figure 33 Total Incident cases of Osteosarcoma in Spain (2017–2030)

Figure 34 Gender-specific Incident cases of Osteosarcoma in Spain (2017–2030)

Figure 35 Age-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Figure 36 Stage-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Figure 37 Sub-types specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Figure 38 Site-specific Incident Cases of Osteosarcoma in Spain (2017–2030)

Figure 39 Total Incident cases of Osteosarcoma in the United Kingdom (2017–2030)

Figure 40 Gender-specific Incident cases of Osteosarcoma in the United Kingdom (2017–2030)

Figure 41 Age-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Figure 42 Stage-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Figure 43 Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Figure 44 Site-specific Incident Cases of Osteosarcoma in the United Kingdom (2017–2030)

Figure 45 Total Incident cases of Osteosarcoma in Japan (2017–2030)

Figure 46 Gender-specific Incident cases of Osteosarcoma in Japan (2017–2030)

Figure 47 Age-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Figure 48 Stage-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Figure 49 Sub-types specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Figure 50 Site-specific Incident Cases of Osteosarcoma in Japan (2017–2030)

Figure 51 Diagnostic and therapeutic algorithm of osteosarcoma

Figure 52 Unmet needs of Osteosarcoma

Figure 53 Seven Major Market Size of Osteosarcoma in USD Million (2017–2030)

Figure 54 Seven Major Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 55 Market Size of Osteosarcoma in the United States, USD Million (2017–2030)

Figure 56 United States Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 57 United States Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 58 United States Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 59 Market Size of Osteosarcoma in Germany, USD Million (2017–2030)

Figure 60 Germany Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 61 Germany Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 62 Germany Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 63 Market Size of Osteosarcoma in France, USD Million (2017–2030)

Figure 64 France Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 65 France Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 66 France Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 67 Market Size of Osteosarcoma in Italy, USD Million (2017–2030)

Figure 68 Italy Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 69 Italy Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 70 Italy Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 71 Market Size of Osteosarcoma in Spain, USD Million (2017–2030)

Figure 72 Spain Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 73 Spain Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 74 Spain Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 75 Market Size of Osteosarcoma in the United Kingdom, USD Million (2017–2030)

Figure 76 United Kingdom Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 77 United Kingdom Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 78 United Kingdom Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 79 Market Size of Osteosarcoma in Japan, USD Million (2017–2030)

Figure 80 Japan Market Size of Osteosarcoma by Therapies in USD Million (2017–2030)

Figure 81 Japan Market Size of Osteosarcoma (Non-Metastatic) in USD Million (2017–2030)

Figure 82 Japan Market Size of Osteosarcoma (Metastatic) in USD Million (2017–2030)

Figure 83 Market Drivers

Figure 84 Market Barriers

Figure 85 SWOT analysis

Figure 86 Summary of Takeda UK Mifamurtide Patient Access Scheme

Takeda

Acrotech Biopharma

Bayer

Exelixis

Nektar Therapeutics

Eisai

Y-mAbs Therapeutics

GlaxoSmithKline/Novartis

Aadi Bioscience

Vaccinex, Inc.

National Cancer Institute/Assaf-Harofeh Medical Center

Eleison Pharmaceuticals

Aurora biopharma

BioAtla

Iovance Biotherapeutics

Isofol Medical AB

Bristol-Myers Squibb

Cellestia Biotech

  • Tags:
  • Osteosarcoma market
  • Osteosarcoma market research
  • Osteosarcoma market insight
  • Osteosarcoma market trends
  • Osteosarcoma market forecast
  • Osteosarcoma market share
  • Osteosarcoma pipeline drugs
  • Osteosarcoma treatment algorithm

Forward to Friend

Need A Quote